Get the Stockscreener App
2.14
1.83%
-0.04
After Hours:
2.13
-0.01
-0.47%
Overview
News
Price History
Option Chain
Financials
Why SAVA Down?
Discussions
Forecast
Stock Split
Dividend History
Cassava Sciences Inc stock is traded at $2.14, with a volume of 592.92K.
It is down -1.83% in the last 24 hours and down -33.12% over the past month.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
See More
Previous Close:
$2.18
Open:
$2.16
24h Volume:
592.92K
Relative Volume:
0.40
Market Cap:
$103.38M
Revenue:
-
Net Income/Loss:
$-97.22M
P/E Ratio:
-1.5507
EPS:
-1.38
Net Cash Flow:
$-82.44M
1W Performance:
+8.08%
1M Performance:
-33.12%
6M Performance:
+2.88%
1Y Performance:
-24.25%
1-Day Range:
$2.12
$2.19
1-Week Range:
$1.965
$2.28
52-Week Range:
$1.15
$4.98
Cassava Sciences Inc Stock (SAVA) Company Profile
Name
Cassava Sciences Inc
Sector
Industry
Phone
512-501-2444
Address
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
Compare SAVA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SAVA
Cassava Sciences Inc
|
2.14 | 105.31M | 0 | -97.22M | -82.44M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-08-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-16-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-15-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-27-21 | Initiated | B. Riley Securities | Buy |
| Feb-16-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-18-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-20 | Downgrade | Maxim Group | Buy → Hold |
| Jan-10-20 | Reiterated | Maxim Group | Buy |
View All
Cassava Sciences Inc Stock (SAVA) Latest News
Signal Recap: Why Cassava Sciences Inc. Equity Warrant stock appeals to analystsJuly 2025 Trends & Growth Focused Stock Pick Reports - ulpravda.ru
How Cassava Sciences Inc. (PX91) stock reacts to weak economyTrade Performance Summary & AI Driven Price Forecasts - ulpravda.ru
Is Cassava Sciences Inc. stock a dividend growth opportunity - ulpravda.ru
Why Cassava Sciences Inc. (PX91) stock is a must watch tickerWeekly Trend Summary & Trade Opportunity Analysis Reports - ulpravda.ru
How Cassava Sciences Inc. stock responds to policy changesJuly 2025 Trends & Reliable Price Breakout Alerts - ulpravda.ru
Published on: 2026-01-09 03:02:15 - ulpravda.ru
Does Cassava Sciences Inc. Equity Warrant stock trade at a discount to peers2025 Market Sentiment & Free Verified High Yield Trade Plans - ulpravda.ru
Why Cassava Sciences Inc. Equity Warrant stock appeals to analystsMarket Trend Report & Technical Pattern Based Signals - ulpravda.ru
Why Cassava Sciences Inc. Equity Warrant stock is in analyst buy zoneJuly 2025 Reactions & Entry Point Confirmation Signals - ulpravda.ru
Why Cassava Sciences Inc. Equity Warrant stock remains a top recommendationREITs Market Trends & Big Gains Small Capital - ulpravda.ru
Investors Buy Large Volume of Call Options on Cassava Sciences (NASDAQ:SAVA) - MarketBeat
2026 world cup star players odds: Why Cassava Sciences Inc. Equity Warrant stock remains undervalued2026 world cup usa national team round of 16 playmakers counter attacking expert forecast expert opinion - ulpravda.ru
Sector Leaders Rotate Capital Into VCU Data Management LimitedTop Performing Stocks & Free Significant Capital Appreciation - earlytimes.in
Aug Reactions: Will Cassava Sciences Inc stock reach all time highs in 2025Market Sentiment Review & Low Volatility Stock Suggestions - moha.gov.vn
Multi Factor Analysis Ranks Ekansh Concepts Limited as Strong BuyStock Price Targets & Register for the Next Free Workshop - earlytimes.in
Quarterly Earnings: Will Cassava Sciences Inc stock see insider buyingInsider Selling & Weekly Watchlist for Hot Stocks - moha.gov.vn
HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - The Malaysian Reserve
Cassava Sciences settles securities class action for $31.25 million By Investing.com - Investing.com Australia
Cassava Sciences agrees to settle long-running investor lawsuit - The Business Journals
Cassava Sciences agrees to $31.25 million settlement in securities class action By Investing.com - Investing.com Nigeria
Cassava Sciences agrees to $31.25 million settlement in securities class action - Investing.com
Cassava Sciences Agrees to Pay $31.25 Million to Settle Securities Class Action - marketscreener.com
[8-K] CASSAVA SCIENCES INC Reports Material Event | SAVA SEC FilingForm 8-K - Stock Titan
Cassava settles securities class action suit (SAVA:NASDAQ) - Seeking Alpha
Cassava Sciences settles securities class action for $31.25 million - Investing.com
Cassava Sciences, Inc. Reaches $31.25 Million Settlement in Consolidated Securities Class Action Litigation - Quiver Quantitative
Cassava announces agreement to settle securities class action litigation - marketscreener.com
Cassava Announces Agreement to Settle Securities Class Action Litigation - GlobeNewswire
Cassava Sciences Shares Plunge After FDA Intervention - AD HOC NEWS
Published on: 2025-12-22 08:32:25 - Улправда
Can Cassava Sciences Inc. stock outperform in 2025 bull marketQuarterly Portfolio Report & Low Drawdown Momentum Trade Ideas - Улправда
Why Cassava Sciences Inc. Equity Warrant stock appeals to dividend seekersWeekly Earnings Recap & Reliable Price Breakout Alerts - Улправда
Cassava Sciences (NASDAQ:SAVA) Stock Price Down 23.9%What's Next? - MarketBeat
Will Cassava Sciences Inc. stock benefit from sector rotationQuarterly Investment Review & Real-Time Stock Price Movement Reports - Улправда
Cassava Sciences stock on track for worst day in about 9 months — what’s driving today’s selloff? - MSN
Cassava Sciences Stock On Track For Worst Day In About 9 Months — What’s Driving Today’s Selloff? - Asianet Newsable
FDA Puts Cassava's Simufilam Epilepsy Trial On Full Clinical Hold - Benzinga
Cassava Sciences stock falls after FDA places clinical trial on hold By Investing.com - Investing.com South Africa
Cassava Sciences stock falls after FDA places clinical trial on hold - Investing.com Australia
Cassava Sciences Shares Fall Pre-Bell After FDA Clinical Hold on Simufilam Trial - marketscreener.com
Cassava Sciences down on delay for epilepsy study (SAVA:NASDAQ) - Seeking Alpha
Why Cassava Sciences Inc. Equity Warrant stock remains undervaluedPortfolio Performance Report & Weekly Return Optimization Plans - Улправда
Cassava Sciences IncOn Dec 15, FDA places full clinical hold on Cassava's trialSEC filing - marketscreener.com
Cassava Sciences receives FDA clinical hold on simufilam trial for TSC epilepsy By Investing.com - Investing.com South Africa
Cassava Sciences receives FDA clinical hold on simufilam trial for TSC epilepsy - Investing.com Nigeria
FDA Places Clinical Hold on Cassava’s Epilepsy Trial - TipRanks
Cassava Sciences Receives FDA Clinical Hold on Simufilam Trial - TradingView — Track All Markets
Published on: 2025-12-18 21:27:30 - Улправда
Cassava Sciences Inc Stock (SAVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
4.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):